Adrenergic agonists and antagonists in the treatment of hypovolemic shock.
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D004298:Dopamine / Q000627:therapeutic use; D004837:Epinephrine / Q000627:therapeutic use; D006801:Humans; D007545:Isoproterenol / Q000627:therapeutic use; D008680:Metaraminol / Q000627:therapeutic use; D009638:Norepinephrine / Q000627:therapeutic use; D010643:Phenoxybenzamine / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D012769:Shock / Q000188:drug therapy*; D013565:Sympatholytics / Q000627:therapeutic use*; D013566:Sympathomimetics / Q000627:therapeutic use*
D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D013565:Sympatholytics; D013566:Sympathomimetics; D010643:Phenoxybenzamine; D008680:Metaraminol; D011433:Propranolol; D007545:Isoproterenol; D004298:Dopamine; D009638:Norepinephrine; D004837:Epinephrine